Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. May 21, 2014; 20(19): 5875-5880
Published online May 21, 2014. doi: 10.3748/wjg.v20.i19.5875
Published online May 21, 2014. doi: 10.3748/wjg.v20.i19.5875
Table 1 Standardized maximum uptake value or serum carbohydrate antigen 19-9 of pancreatic cancer stratified by stage, differentiation, lymph node and tumor size
n | SUVmax (n = 80) | Serum CA19-9 (n = 80) | |||
mean ± SE | P value | mean ± SE | P value | ||
Sex | |||||
Male | 48 | 5.73 ± 0.36 | 0.091 | 749.30 ± 72.99 | 0.102 |
Female | 32 | 6.91 ± 0.64 | 981.31 ± 132.74 | ||
Age (yr) | |||||
≤ 60 | 37 | 5.74 ± 0.42 | 0.206 | 766.43 ± 93.14 | 0.316 |
> 60 | 43 | 6.60 ± 0.52 | 907.22 ± 101.44 | ||
Pancreatic location (n) | |||||
Head | 62 | 6.39 ± 0.41 | 0.293 | 871.46 ± 84.01 | 0.437 |
Body or tail | 18 | 5.53 ± 0.50 | 740.99 ± 108.47 | ||
Stage | |||||
I/II | 55 | 5.83 ± 0.43 | 0.110 | 729.09 ± 71.31 | 0.035 |
III/IV | 25 | 7.01 ± 0.49 | 1090.74 ± 148.23 | ||
Pathological differentiation | |||||
Well | 28 | 5.46 ± 0.52 | 0.110 | 720.83 ± 99.27 | 0.055 |
Moderate | 18 | 5.81 ± 0.62 | 667.87 ± 126.90 | ||
Poor | 34 | 0.70 ± 0.57 | 1034.22 ± 119.19 | ||
Tumor size | |||||
> 2 cm | 56 | 6.32 ± 0.40 | 0.584 | 901.61 ± 87.16 | 0.193 |
≤ 2 cm | 24 | 5.91 ± 0.65 | 703.27 ± 108.27 | ||
Lymph node metastasis | |||||
Yes | 34 | 6.54 ± 0.52 | 0.017 | 831.84 ± 90.02 | 0.172 |
No | 25 | 4.72 ± 0.50 | 634.35 ± 112.96 | ||
Distant metastasis | |||||
Yes | 8 | 7.48 ± 0.89 | 0.210 | 1363.26 ± 338.95 | 0.134 |
No | 72 | 6.06 ± 0.36 | 784.20 ± 65.13 | ||
R0 surgical resection | |||||
Yes | 59 | 5.79 ± 0.38 | 0.043 | 731.19 ± 71.35 | 0.007 |
No | 21 | 7.35 ± 0.67 | 1153.72 ± 156.96 |
Table 2 Univariate analysis of prognostic factors for overall survival
Variable | n | P value |
Sex | ||
Male | 48 | 0.119 |
Female | 32 | |
Age (yr) | ||
≤ 60 | 37 | 0.993 |
> 60 | 43 | |
Pancreatic location (n) | ||
Head | 62 | 0.378 |
Body or tail | 18 | |
Stage | ||
I/II | 55 | < 0.001 |
III/IV | 25 | |
Pathological differentiation | ||
Well | 28 | 0.697 |
Moderate | 18 | |
Poor | 34 | |
Tumor size | ||
> 2cm | 56 | 0.339 |
≤ 2cm | 24 | |
Lymph node metastasis | ||
Yes | 34 | 0.043 |
No | 25 | |
Distant metastasis | ||
Yes | 8 | < 0.001 |
No | 72 | |
Surgical resection | ||
Yes | 59 | < 0.001 |
No | 21 | |
SUVmax | ||
High | 40 | < 0.001 |
Low | 40 | |
CA19-9 | ||
High | 40 | 0.001 |
Low | 40 | |
SUVmax plus CA19-9 | ||
Both are high | 29 | 0.002 |
Others | 51 |
Table 3 Multivariate analysis of prognostic factors for overall survival
Variable | Hazard ratio (95%CI) | P value |
Stage | 0.452 (0.192-1.064) | 0.020 |
Lymph node metastasis | 0.786 (0.418-1.478) | 0.455 |
Surgical resection | 11.521 (0.799-166.191) | 0.073 |
SUVmax | 0.553 (0.216-1.413) | 0.216 |
CA19-9 | 0.452 (0.192-1.064) | 0.069 |
SUVmax plus CA19-9 | 1.558 (0.439-5.525) | 0.493 |
- Citation: Zhao JG, Hu Y, Liao Q, Niu ZY, Zhao YP. Prognostic significance of SUVmax and serum carbohydrate antigen 19-9 in pancreatic cancer. World J Gastroenterol 2014; 20(19): 5875-5880
- URL: https://www.wjgnet.com/1007-9327/full/v20/i19/5875.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i19.5875